ReviewPCN reports : psychiatry and clinical neurosciences2026
Asenapine for delirium in patients with cancer: A scoping review.
Review in PCN reports : psychiatry and clinical neurosciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This scoping review mapped the existing literature on the application of asenapine for delirium management in patients with cancer, including prevention and treatment, while summarizing current research trends. The review followed the methodological framework proposed by Arksey and O'Malley and was reported in accordance with the Preferred Reporting Items for Systematic reviews and Meta-Analyses Extension for Scoping Reviews. PubMed and Ichushi-Web were searched on June 30, 2025, using the keywords "asenapine," "delirium," and "cancer." Eligible studies included reports on asenapine management for delirium in patients with cancer. Two reviewers independently screened records and extracted data. Among the six records identified, three studies met the inclusion criteria and were included in this review. Two of these were retrospective observational studies, and one was a case report. One retrospective study described six terminally ill patients treated with sublingual asenapine, showing marked improvement in agitation, as measured using the Richmond Agitation-Sedation Scale. The other study analyzed 20 patients with advanced cancer and reported reductions in the Agitation Distress Scale scores, particularly among those with poor performance status. Moreover, this case report highlighted the successful use of sublingual asenapine in a patient with aphagia unresponsive to other antipsychotic agents. Across the studies, asenapine was generally well-tolerated, with one suspected dysarthria and no serious adverse events. The current evidence is limited in quantity and quality, and no preventive studies were identified. While preliminary findings suggest that sublingual asenapine may be useful and well-tolerated for treating delirium in patients with cancer, further high-quality studies are warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.